公开(公告)号：WO2020050633A1

公开(公告)日：2020-03-12

申请号：PCT/KR2019/011432

申请日：2019-09-04

Applicant: 한국식품연구원

Inventor： 신희순 ,  김승용 ,  신동욱 ,  엄지은 ,  이소영 ,  정선영 ,  최대운 ,  남영도 ,  박소림

IPC: A61K36/704 ,  A61K36/47 ,  A61P29/00 ,  A61P37/08 ,  A61P11/06 ,  A61P11/00 ,  A23L33/105

Abstract: 본 발명은 갯대추나무, 생열귀나무, 소태나무, 차나무, 괭이눈, 호장근, 모과나무, 산수국 및/또는 화살나무 추출물을 이용한 천식 또는 만성폐쇄성폐질환 등의 폐질환 개선용 조성물을 개시한다. 갯대추나무, 생열귀나무, 소태나무, 차나무, 괭이눈, 호장근, 모과나무, 산수국 및/또는 화살나무 추출물은 PMA(phorbol myristate acetate)에 의해 유도된 호중구 세포외 트랩(Neutrophil extracellular traps)의 네토시스(Netosis) 활성화를 억제하고, 점액질을 생성하는 기관지 상피세포주인 NCI-H292 세포의 CSE에 의한 염증성 사이토카인인 IL-8의 발현을 억제하며, CES와 LPS(lipopolysaccaride)에 의해 활성된 폐포 대식세포인 MH-S 세포의 염증성 사이토카인인 MIP-2의 발현을 억제하는 활성을 가진다. 또한, CSE와 PPE로 유도된 호흡기 질환 마우스 모델에서 폐 조직 손상을 억제하고, BALF 내에 총 세포(Total cell), 대식세포(macrophages), 림프구(Lymphocytes), 호산구(Eosinophil), 호중구(Neutrophil) 등의 면역세포 침윤을 억제하며, BALF 및 폐 조직에서 염증성 사이토카인과 케모카인 분비를 억제하는 활성을 가진다.

公开(公告)号：WO2019238254A1

公开(公告)日：2019-12-19

申请号：PCT/EP2018/078444

申请日：2018-10-17

Applicant: SETONDA, S.L.

Inventor： YUSUBOV, Natig

IPC: A61K36/11 ,  A61K36/18 ,  A61K36/36 ,  A61K36/33 ,  A61K36/53 ,  A61K36/899 ,  A61K36/28 ,  A61K36/47 ,  A61P13/02 ,  A61P13/04 ,  A61P13/12 ,  A61P19/06 ,  A61P1/06 ,  A61P31/04 ,  A61P39/00

Abstract: Present invention relates to a herbal composition for the treatment of urolithiasis (kidney stones), and prophylaxis of re-formation of stones after passing them, for the treatment of gout, and for inhibition of excessive amount of salts (urates, oxalates, phosphates, carbonates) in kidneys, for the treatment of dysuria phenomenon (pollakiuria, strangury, dysuria, nycturia, low urinary pressure and urinary continence), and of urinary and biliary tract spasm, spastic colitis, different poisoning types (drugs, alcohol, medications, food poisoning), for the treatment of asymptomatic bacteriuria and for the treatment of urinary tract infections (cystitis, urethritis, pyelonephritis etc.), wherein its production is disclosed by using herbal composition comprising Equisetum arvense at a concentration of 3%-67% by weight, spergularia rubra at a concentration of 2%-38% by weight, peumus boldus at a concentration of 1.5%-32% by weight, opuntia ficus indica at a concentration of 1 %-20% by weight, sideritis angustifolia at a concentration of 1 -20% by weight, rosmarinus officinalis at a concentration of 1-20% by weight, cynodon dactylon at a concentration of 1 -20% by weight and melissa officinalis at a concentration of 1 -20% by weight, and vapor distillation method.

公开(公告)号：WO2017210559A1

公开(公告)日：2017-12-07

申请号：PCT/US2017/035687

申请日：2017-06-02

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： CHAPMAN, Harold, A. ,  WEI, Ying ,  BACKES, Bradley, J.

IPC: A61K36/185 ,  A61K36/47 ,  A61K36/13

Abstract: Provided herein, inter alia , are methods and compounds for treating a pulmonary disease, fibrosis, or cancer.

Abstract translation: 本文提供的，尤其是用于治疗肺部疾病，纤维化或癌症的方法和化合物。

公开(公告)号：WO2016150860A1

公开(公告)日：2016-09-29

申请号：PCT/EP2016/055989

申请日：2016-03-18

Applicant: PHYTON BIOTECH GMBH

Inventor： GORR, Gilbert ,  ULLISCH, David Alexander ,  SANKAR-THOMAS, Yantree Devi ,  SELGE, Thomas ,  LEIBOLD, Thomas ,  HECKENMÜLLER, Harald

IPC: A01H4/00 ,  A61K36/47 ,  C12N5/00 ,  C12N5/04

CPC classification number: A01H4/001 ,  A61K36/47 ,  C12N5/0025 ,  C12N5/04

Abstract: The present invention relates to a method of producing Ingenol, Ingenol esters and/or Tiglian- 3-one derivatives, the method comprising the steps of: (a) culturing plant cells obtained from a plant selected from the family Euphorbiaceae in a nutrient medium in a suspension cell culture, wherein the cells produce Ingenol, one or more Ingenol esters and/or one or more Tiglian-3-one derivatives; and (b) recovering the Ingenol, the one or more Ingenol esters and/or the one or more Tiglian-3-one derivatives produced in (a). The present invention further relates to a plant suspension cell culture, wherein the cells are obtained from a plant selected from the family Euphorbiaceae, and wherein the plant cells produce Ingenol and/or one or more Ingenol ester and/or one or more Tiglian-3-one derivatives. The present invention further relates to a plant cell biomass comprising plant cells obtained from the suspension cell culture of the invention, and comprising Ingenol and/or one or more Ingenol esters and/or one or more Tiglian-3-one derivatives. Also, the present invention relates to cryopreserved cells of the plant suspension cell culture of the invention as well as to a method of producing Ingenol, Ingenol esters and/or Tiglian-3-one derivatives based on these cryopreserved cells.

Abstract translation: 本发明涉及一种生产茚基，异基因酯和/或噻吩-3-酮衍生物的方法，所述方法包括以下步骤：（a）从营养培养基中培养从选自桉树科植物的植物获得的植物细胞 悬浮细胞培养物，其中细胞产生Ingenol，一种或多种Ingenol酯和/或一种或多种Tiglian-3-one衍生物; 和（b）回收Ingenol，一种或多种Ingenol酯和/或（a）中产生的一种或多种Tiglian-3一类衍生物。 本发明还涉及一种植物悬浮细胞培养物，其中所述细胞从选自大戟科的植物中获得，并且其中所述植物细胞产生Ingenol和/或一种或多种Ingenol酯和/或一种或多种Tiglian-3 一个衍生物。 本发明还涉及包含从本发明的悬浮细胞培养物获得并含有Ingenol和/或一种或多种Ingenol酯和/或一种或多种Tiglian-3-one衍生物的植物细胞的植物细胞生物质。 此外，本发明还涉及本发明的植物悬浮细胞培养物的冷冻保存细胞，以及基于这些冷冻保存细胞产生茚基，异基因酯和/或噻嗪-3-酮衍生物的方法。

公开(公告)号：WO2016078032A1

公开(公告)日：2016-05-26

申请号：PCT/CN2014/091612

申请日：2014-11-19

Applicant: 杨武松

Inventor： 杨武松

IPC: A61K36/53 ,  A61K36/47 ,  A61K36/28 ,  A61K36/21 ,  A61K9/127 ,  A61P25/00 ,  A61P29/00

CPC classification number: A61K9/127 ,  A61K36/21 ,  A61K36/28 ,  A61K36/47 ,  A61K36/53

Abstract: 一种具有缓解酸痛功能的多种天然植物萃取液混合制剂及其制法，该制剂包含：苋科萃取液13-17％，如野苋菜；唇形科萃取液18-22％，如仙草；第一大戟科萃取液28-32％，如大飞扬草；及第一菊科萃取液23-27％，如胜红蓟。该制剂的制法包含：将上述萃取液与油脂搅拌，将搅拌后的混合液在高压下均质乳化。

公开(公告)号：WO2015184111A1

公开(公告)日：2015-12-03

申请号：PCT/US2015/032927

申请日：2015-05-28

Applicant: JAGUAR ANIMAL HEALTH, INC.

Inventor： MARTINOD, Serge

IPC: A61K36/47

CPC classification number: A61K31/353 ,  A23K10/30 ,  A23K50/10 ,  A23K50/20 ,  A23K50/60 ,  A61K9/006 ,  A61K9/0068 ,  A61K9/0095 ,  A61K9/06 ,  A61K9/5021 ,  A61K9/51 ,  A61K36/47 ,  A61K45/06 ,  Y02A50/481

Abstract: Provided are methods of treating diarrhea, particularly malabsorption diarrhea, in neonatal, young and adult non-human animals, in which the diarrhea results from infection of the animals by Salmonella spp., such as Salmonella typhimurium, with a therapeutically effective amount of a proanthocyanidin polymer from Croton lechleri, in either enteric or non-enteric form.

Abstract translation: 提供了在新生儿，年轻和成年的非人类动物中治疗腹泻，特别是吸收不良的方法，其中腹泻是由沙门氏菌感染的动物，如鼠伤寒沙门氏菌，具有治疗有效量的原花色素 来自Croton lechleri的聚合物，无论是肠道还是非肠道形式。

公开(公告)号：WO2015184109A1

公开(公告)日：2015-12-03

申请号：PCT/US2015/032920

申请日：2015-05-28

Applicant: JAGUAR ANIMAL HEALTH, INC.

Inventor： MARTINOD, Serge

IPC: A61K36/47

CPC classification number: A61K36/47 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/006 ,  A61K9/0095 ,  A61K9/06 ,  A61K31/353 ,  A61K35/74 ,  A61K2300/00

Abstract: Methods of treating adult non-human animals afflicted with diarrhea, particularly, stress-induced diarrhea, by administering to an animal in need thereof an effective amount of a pharmaceutical formulation of a proanthocyanidin polymer composition isolated from a Croton spp. or a Calophyllum spp. are provided. In particular, the adult animals include horses and camels which frequently suffer from stress-induced diarrhea and its symptoms, and the administered proanthocyanidin polymer composition is isolated from a Croton lechleri . The composition, which can be enteric or non-enteric, is administered particularly to target the intestine/gut of the animal via a mode and under conditions conducive and sufficient for providing effective treatment of diarrhea in the affected animal. Preferred modes of administration include orally providing an effective concentration of the proanthocyanidin polymer composition, e.g., via an oral paste formulation, drench, animal feed, or water bottle, to the affected animal.

Abstract translation: 通过向有需要的动物施用有效量的从巴豆属分离的原花色素聚合物组合物的药物制剂，治疗腹泻特别是应激性腹泻的成人非人动物的方法。 或Calophyllum spp。 被提供。 特别地，成年动物包括经常遭受压力引起的腹泻及其症状的马和骆驼，并且从Croton lechleri分离所施用的原花色素聚合物组合物。 可以通过模式和在有利于和足以提供有效治疗受影响的动物的腹泻的条件下对肠道或非肠道的组合物进行施用以靶向动物的肠/肠。 优选的给药方式包括口服提供有效浓度的原花青素聚合物组合物，例如通过口服糊剂制剂，灌洗剂，动物饲料或水瓶给受影响的动物。

公开(公告)号：WO2015052728A1

公开(公告)日：2015-04-16

申请号：PCT/IN2014/000642

申请日：2014-10-07

Applicant: ANTONY, Benny

Inventor： ANTONY, Benny

IPC: A61K36/00 ,  A61K36/47

CPC classification number: A61K36/47

Abstract: A composition having an extract of seed of Emblica officinalis . Methods of preparing extract of seed of Emblica officinalis . An amla seed blend composition having various ratios of extracts of seeds of Emblica officinalis . Nutraceutical or pharmaceutical methods for decreasing the total cholesterol, decreasing triglyceride, decreasing blood glucose level, enhancing HDL-C levels, increasing the HDL-C level to total cholesterol ratio, lowering LDL- C levels, decreasing the CRP level, decreasing the intima media thickening, reducing hair fall in mammals especially human beings. The extract of seed of Emblica officinalis , or the amla seed blend composition is more effective compared to extracts prepared from fruits of Emblica officinalis .

Abstract translation: 一种具有刺桐种子提取物的组合物。 芹菜种子提取方法。 具有各种比例的Emblica officinalis种子提取物的阿米拉种子混合组合物。 用于降低总胆固醇，降低甘油三酯，降低血糖水平，提高HDL-C水平，将HDL-C水平升高为总胆固醇比的营养或药物方法，降低LDL-C水平，降低CRP水平，减少内膜介质 增厚，减少哺乳动物特别是人类的头发掉落。 与从槟榔的果实制备的提取物相比，Emblica officinalis的种子提取物或amla种子混合物组合物更有效。

公开(公告)号：WO2015001574A1

公开(公告)日：2015-01-08

申请号：PCT/IN2014/000446

申请日：2014-07-04

Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH

Inventor： NAUTIYAL, Chandra Shekhar ,  KUMAR, Dinesh ,  RAWAT, Ajay Kumar Singh ,  AGARWAL, Sudha ,  MANI, Dayanandan ,  OJHA, Sanjeev Kumar ,  PAL, Anirban ,  RAO, Chandana Venkateswara ,  DAROKAR, Mahendra Pandurang ,  KALRA, Alok

IPC: A24B15/16 ,  A61K36/75 ,  A61K36/9064 ,  A61K36/185 ,  A61K36/235 ,  A61K36/47 ,  A61K36/48 ,  A61K36/49 ,  A61K36/534

CPC classification number: A24B15/16 ,  A61K36/00

Abstract: The present invention provides a nicotine free synergistic polyherbal masticatory formulation and a process for the preparation thereof. The prepared formulation exhibits tobacco de-addiction properties and is envisaged to replace tobacco based harmful products. The formulation of the present invention is useful as a tobacco supplement or a tobacco substitute for use in smoking cessation, tobacco chewing urge and nicotine replacement therapies, which provides the user to reduce tobacco withdrawal symptoms without causing unacceptable adverse effects along with health rejuvenation being antimicrobial and antioxidant.

Abstract translation: 本发明提供了一种不含尼古丁的协同性多醛灌浆制剂及其制备方法。 所制备的配方具有烟草脱瘾性质，并被设想用来代替烟草基有害产物。 本发明的制剂可用作用于戒烟，烟草咀嚼和尼古丁替代疗法的烟草补充剂或烟草替代物，其提供使用者减少烟草戒断症状而不引起不可接受的不利影响以及健康年轻化为抗微生物 和抗氧化剂。

公开(公告)号：WO2014178799A1

公开(公告)日：2014-11-06

申请号：PCT/TH2013/000022

申请日：2013-04-30

Applicant: KIETINUN, Somboon ,  ITHARAT, Arunporn

Inventor： KIETINUN, Somboon ,  ITHARAT, Arunporn

IPC: A61K36/8905 ,  A61K36/185 ,  A61K36/47

CPC classification number: A61K36/47 ,  A61K36/185 ,  A61K36/8905

Abstract: The present disclosure relates to botanical composition for treating AIDS having at least IC 50 for anti HIV-1 integrase activity of 0.1-10 microgram/milliliter, IC 50 for anti HIV-1 protease activity of 0.1 - 10 microgram/milliliter and, IC 50 for anti HIV- 1 transcriptase activity of 0.1 - 10 microgram/milliliter. The composition comprises ethanolic extracts from Antidesma acidum Retz.-root (I), Terminalia bellirica (Gaertn.) Roxb.-fruit(II) and Cyperus rotundus Linn. -rhizome (III) at a ratio of 5:4: 1 by weight. The mixture is prepared in pharmaceutical preparation as capsule, soft capsule, suspension, elixir, emulsion, tablet or film-coated tablet. When the composition is given to AIDS patients, the viral load log was found to decrease progressively within 6 months.

Abstract translation: 本公开内容涉及用于治疗AIDS的植物药物组合物，其具有0.1-10微克/毫升抗HIV-1整合酶活性的至少IC 50，抗HIV-1蛋白酶活性的IC 50为0.1〜10微克/毫升，抗HIV的IC 50 - 1个转录酶活性为0.1-10微克/毫升。 该组合物包括来自Antidesma acidum Retz.-root（I），Terminalia bellirica（Gaertn。）Roxb.-fruit（II）和Cyperus rotundus Linn的乙醇提取物。 （III），重量比为5：4：1。 该混合物在药物制剂中制备为胶囊，软胶囊，悬浮液，酏剂，乳剂，片剂或薄膜包衣片剂。 当给艾滋病患者提供组合时，发现病毒载量记录在6个月内逐渐下降。